A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03010475|
Recruitment Status : Completed
First Posted : January 5, 2017
Last Update Posted : December 20, 2017
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Healthy||Drug: Furosemide Drug: Rosuvastatin Drug: SNAC Drug: Semaglutide||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||41 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects.|
|Actual Study Start Date :||January 5, 2017|
|Actual Primary Completion Date :||June 4, 2017|
|Actual Study Completion Date :||August 9, 2017|
Oral administration A total of three single doses.
Oral administration. A total of three single doses.
Oral administration. A total of five single doses.
Oral administration. Once daily.
- Area under the furosemide plasma concentration-time curve [ Time Frame: day 1, day 7, day 54 ]Based on sampling between 0 and 12 hours
- Area under the rosuvastatin plasma concentration-time curve [ Time Frame: day 2, day 8, day 55 ]Based on sampling between 0 and 96 hours
- Maximum observed furosemide plasma concentration [ Time Frame: day 1, day 7, day 54 ]
- Maximum observed rosuvastatin plasma concentration [ Time Frame: day 2, day 8, day 55 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03010475
|Novo Nordisk Investigational Site|
|Harrow, United Kingdom, HA1 3UJ|